Option chain shows key data for Senti Biosciences's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Senti Biosciences.

Senti Biosciences (NASDAQ:SNTI) Stock, Option Chain

SENTI BIOSCIENCES INC

Senti Biosciences

Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.

AT&T

News

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

BASE

HNST

MRVL

SNTI

TRMB

AT&amp;T To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Wednesday

Fat Bear Week Returns

Equities

General

$BTC

INTC

SHIM

SMCI

TSLA

U.S. stock futures were in negative territory during Tuesday’s premarket hours as the dollar slipped to 106.3 level.

US Stock Futures Dip As Dollar Slides And Treasuries Rise After S&amp;P Hits 54th All-Time High This Year: Analyst Sees &#39;Further Upside&#39; Of Around 10% In 2025 From Current Levels

Wall street.Stockmarket.Stock,Traders,Pointing,Highest,Stock,Market,On,Dynamic,Valued,Analysis

Earnings

Eurozone

Commodities

MOND

NVCR

RVMD

UPST

Dow Dips 150 Points; ISM Manufacturing PMI Tops Estimates

Senti Biosciences Inc

Health Care

Press Releases

Senti Bio Joins Webull Corporate Connect Service Platform

Management

Senti Bio Bolsters Scientific Advisory Board with Appointment of James B. Trager, Ph.D.

Senti Bio (NASDAQ: SNTI) to Participate in a Live Virtual Investor Closing Bell Segment

Senti Bio Participates in a Virtual Investor KOL Connect Segment

Senti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 on Monday, April 28th at 8:30 AM ET

Senti Bio's SENTI-202, a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AML

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI

Senti Bio to Present at the Citizens JMP Life Sciences Conference

Senti Bio Releases Virtual Investor "What This Means" Segment

Legal

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Senti Biosciences, Inc. – SNTI

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Agenus

Anixa Biosciences

Biomea Fusion

Climb Bio

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals

Caribou Biosciences

CervoMed

Elicio Therapeutics

Elutia

EXoZymes

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

IGM Biosciences

I-MAB

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

Seres Therapeutics

OncoCyte

Pyxis Oncology

Sutro Biopharma

TScan Therapeutics

Instil Bio

Tenaya Therapeutics

Vor Biopharma

Whitehawk Therapeutics, Inc. - Common Stock

Whitehawk Therapeutics

XBiotech

Chardan Capital

Morgan Stanley

B of A Securities

Comments

Senti Biosciences

Senti Biosciences (SNTI) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell